Literature DB >> 32945654

Current Perspectives on Therapies, Including Drug Delivery Systems, for Managing Glioblastoma Multiforme.

Mahendran Bhaskaran1, Vishakante Gowda Devegowda1, Vishal Kumar Gupta1, Amruthesh Shivachar2, Rohit Rajendra Bhosale3, Muthuraman Arunachalam4, Thirumalaraju Vaishnavi5.   

Abstract

Glioblastoma multiforme (GBM), a standout among the most dangerous class of central nervous system (CNS) cancer, is most common and is an aggressive malignant brain tumor in adults. In spite of developments in modality therapy, it remains mostly incurable. Consequently, the need for novel systems, strategies, or therapeutic approaches for enhancing the assortment of active agents meant for GBM becomes an important criterion. Currently, cancer research focuses mainly on improving the treatment of GBM via diverse novel drug delivery systems. The treatment options at diagnosis are multimodal and include radiation therapy. Moreover, significant advances in understanding the molecular pathology of GBM and associated cell signaling pathways have opened opportunities for new therapies. Innovative treatment such as immunotherapy also gives hope for enhanced survival. The objective of this work was to collect and report the recent research findings to manage GBM. The present review includes existing novel drug delivery systems and therapies intended for managing GBM. Reported novel drug delivery systems and diverse therapies seem to be precise, secure, and relatively effective, which could lead to a new track for the obliteration of GBM.

Entities:  

Keywords:  Glioblastoma multiforme; delivery systems; drug targets; epidemiology; pathogenesis; therapies

Mesh:

Year:  2020        PMID: 32945654     DOI: 10.1021/acschemneuro.0c00555

Source DB:  PubMed          Journal:  ACS Chem Neurosci        ISSN: 1948-7193            Impact factor:   4.418


  5 in total

1.  Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma.

Authors:  Virginia Aragon-Sanabria; Anusha Aditya; Li Zhang; Ulrich Wiesner; Michelle S Bradbury; Feng Chen; Barney Yoo; Tianye Cao; Brian Madajewski; Rachel Lee; Melik Z Turker; Kai Ma; Sebastien Monette; Peiming Chen; Jing Wu; Shutian Ruan; Michael Overholtzer; Pat Zanzonico; Charles M Rudin; Cameron Brennan
Journal:  Clin Cancer Res       Date:  2022-07-01       Impact factor: 13.801

2.  HOTTIP Mediated Therapy Resistance in Glioma Cells Involves Regulation of EMT-Related miR-10b.

Authors:  Zhang Li; Ming Li; Pengcheng Xia; Zhiming Lu
Journal:  Front Oncol       Date:  2022-03-24       Impact factor: 6.244

3.  Fabrication and Modelling of a Reservoir-Based Drug Delivery System for Customizable Release.

Authors:  Margarethe Hauck; Jan Dittmann; Berit Zeller-Plumhoff; Roshani Madurawala; Dana Hellmold; Carolin Kubelt; Michael Synowitz; Janka Held-Feindt; Rainer Adelung; Stephan Wulfinghoff; Fabian Schütt
Journal:  Pharmaceutics       Date:  2022-04-02       Impact factor: 6.525

4.  Identification of CD73 as the Antigen of an Antigen-Unknown Monoclonal Antibody Established by Exosome Immunization, and Its Antibody-Drug Conjugate Exerts an Antitumor Effect on Glioblastoma Cell Lines.

Authors:  Takahiro Anzai; Shinji Saijou; Hiroki Takashima; Misato Hara; Shingo Hanaoka; Yasuhiro Matsumura; Masahiro Yasunaga
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-06

5.  Ubiquitin-Specific Protease 6 n-Terminal-like Protein (USP6NL) and the Epidermal Growth Factor Receptor (EGFR) Signaling Axis Regulates Ubiquitin-Mediated DNA Repair and Temozolomide-Resistance in Glioblastoma.

Authors:  I-Chang Su; Yu-Kai Su; Hao-Yu Chuang; Vijesh Kumar Yadav; Syahru Agung Setiawan; Iat-Hang Fong; Chi-Tai Yeh; Hui-Chuan Huang; Chien-Min Lin
Journal:  Biomedicines       Date:  2022-06-28
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.